Abstract
The successful in vivo implementation of gene expression modulation strategies relies on effective, non-immunogenic delivery vehicles. Lipid nanoparticles (LNPs) are one of the most advanced, non-viral clinically approved nucleic-acid delivery systems. Yet, LNPs accumulate naturally in liver cells upon intravenous administration and hence there is an urgent need to enhance uptake by other cell types. Here we use a conformation-sensitive targeting strategy to achieve in vivo gene silencing in a selective subset of leukocytes and show potential therapeutic applications in a murine model of colitis. In particular, by targeting the high-affinity (HA) conformation of α4β7 integrin, which is a hallmark of inflammatory, gut-homing leukocytes, we silenced interferon γ in the gut resulting in an improved therapeutic outcome in experimental colitis. The LNPs did not induce adverse immune activation or liver toxicity. These results suggests that our LNP targeting strategy might be applied for selective delivery of payloads to other conformation-sensitive targets.
Accepted Version
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
